Quanome Technologies closed at $0.39 on Nov 4, down 10.07%, 54.1% below its highest close since Sep 11. Volume of 172.8K shares was 0.03× its 20-day average (below normal).
Split-adjusted performance: -25.2% over one month.
Short interest was 831.3K shares at the Oct 15 settlement, up 79.1% from the prior report (2.9% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 83 companies (100 = best)
Industry medians: 6-month return −1.7%, revenue growth +15.3%, net margin 3.2%, P/E 19.7×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| QNMEQuanome Technologies | $0.3903 | −10.07% | — | — | — | — | $13.4M | |
| SOARSOAR AI | $0.2220 | −2.76% | −14.6% | −96.1% | −212.5% | — | $11.9M | Compare |
| NTRPNextTrip | $1.19 | +3.03% | −54.2% | −27.8% | −686.3% | — | $18.0M | Compare |
| EURKEureka Acquisition | $11.50 | −0.43% | +1.2% | — | — | — | $25.0M | Compare |
| OMEXOdyssey Marine Exploration | $11.72 | +4.64% | −63.9% | +78.6% | −4262.9% | — | $27.5M | Compare |
| BTOCArmlogi Holding | $2.16 | −8.47% | −53.2% | −15.3% | −12.6% | — | $6.1M | Compare |
| FJETStarfighters Space | $0.8502 | −0.87% | −83.6% | — | — | — | $46.8M | Compare |
| JTAIJet.AI | $1.00 | 0.00% | −87.0% | +139.0% | −42.8% | 0.7 | $3.6M | Compare |
| FLYXflyExclusive | $1.02 | +7.37% | −59.0% | +21.7% | −7.8% | — | $53.2M | Compare |
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology